Ose Immunotherapeutics Sa · EURONEXT:OSE
Ose Immunotherapeutics Sa — Investor Presentation (April 2026)
31 slides from Ose Immunotherapeutics Sa's investor presentation, Apr 20, 2026
Slide 1: Delivering on Our 3-Year Value Enhancing Strategic Plan
Delivering on Our 3-Year Value Enhancing Strategic Plan 2026 Q2
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains express or implied information and statements that might be deemed This presentation does not constitute an offer to sell the shares or soliciting an offer to purchase any of forward-looking information and statements in respect of OSE Immunothera
Slide 3: A Business Oriented Team to Leverage OSE's Leading R&D Capabilities
A Business Oriented Team to Leverage OSE’s Leading Research and Development Capabilities Marc Le Bozec Thomas Gidoin Sonya Montgomery, ND Silvia Comis, MD Jean-Jacques Mention, PhD Aurore Morello, PhD Chief Executive Officer Deputy Chief Executive Chief Development Chief Clinical and Medical Chief B
Slide 4: Our 3-Year Development Plan Focused on Shareholder Value
Our 3-Year Development Plan Focused on Shareholder Value Strategy to maximize Return on Investment while managing risk: Large Partnered Indications vs • Large indication assets to be developed up to end of Phase 2 Smaller Go-Alone Indications • Smaller indication assets to be developed up to commerc
Slide 5: Clinical Pipeline Focused on Achievable Deliverables
Clinical Pipeline Focused on Achievable Deliverables 3-Year Plan Focused on Proprietary Assets Addressable Product Candidate Target Indication Pre-Clinical Phase 1a/1b Phase 2 Phase 3 Upcoming Milestones Market Ph 2 completed in IV Ph 2b/3 to be licensed out or Lusvertikimab SC Anti-IL-7R Ulcerative
Slide 6: Potential Catalysts Every 6 Months Over Our 3-Year Strategic Plan
Potential Catalysts Every 6 Months Over Our 3-Year Strategic Plan* H1 Tedopi® H1 Lusvertikimab Subcutaneous H1 Tedopi® ISS Phase 2 read-out in Ovarian Cancer Subcutaneous formulation ready for all Phase 3 read-out in HLA-A2+ 2L NSCLC as monotherapy or in combo with indications (Ulcerative Colitis, C
Slide 7: Lusvertikimab
Lusvertikimab Most Advanced Anti-IL-7R mAb Strong biological rationale in refractory IBD patients and inflammatory dermatologic diseases
Slide 8: IL-7 Fuels Chronic Tissues Inflammation – Lusvertikimab Tackles It
Lusvertikimab IL-7 Fuels Chronic Tissues Inflammation – Lusvertikimab Tackles It Upstream mechanism of resistance in hyper-inflammation “…Highly pro-inflammatory cells in the intestinal mucosa in Inflammatory Bowel Disease (IBD) drive molecular resistance to anti-cytokine therapy (such as anti-TNF a
Slide 9: Lusvertikimab – First Pure IL-7 Antagonist that Maintains Healthy Immune System
Lusvertikimab Lusvertikimab – First Pure IL-7 Antagonist that Maintains Healthy Immune System Calming down overexpressed immune response A differentiated IL-7R antagonist solely targeting the immune while maintaining healthy immune response system at the root cause of chronic inflammation • IL-7R pa
Slide 10: Lusvertikimab – Most Advanced and Differentiated First-in-Class Anti-IL-7R mAb
Lusvertikimab Lusvertikimab – Most Advanced and Differentiated First-in-Class Anti-IL-7R mAb Isotype IgG4 IgG1 IgG1 IgG1 • Non-Internalizing1 • TSLP Antagonist • Internalizing • Internalizing • Full Antagonist IL-7R • T-cell Decrease • Antago + Partial Agonist IL-7R • Antago + Partial Agonist IL-7R
Slide 11: Lusvertikimab – A Pragmatic Development Plan
Lusvertikimab Lusvertikimab – A Pragmatic Development Plan Lusvertikimab in Chronic Pouchitis Lusvertikimab in Ulcerative Colitis Rare/Specialist Indication – To be developed by OSE To be Outlicensed or Financed Chronic Antibiotic-Refractory Pouchitis – 45k US/EU/JP patients Ulcerative Colitis – 200
Slide 12: Chronic Antibiotic-Refractory Pouchitis – A Rare IBD Indication
Lusvertikimab Chronic Antibiotic-Refractory Pouchitis – A Rare IBD Indication 45k patients in the US/EU/Japan • Complication of restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) in patients with ulcerative colitis (UC) and familial adenomatous polyposis (FAP). • 30% of UC patients
Slide 13: Chronic Antibiotic-Refractory Pouchitis – Scientific Rationale
Lusvertikimab Chronic Antibiotic-Refractory Pouchitis – Scientific Rationale Cell population frequency IL-7R expressed by CD4/CD8/Th17 IL-7R UC Pochitis IL-7 expressed by TH17 CD8 CD8 CD4 Th17 Memory naïve memory cells Inflammatory disease with similar pathogenesis to UC • Refractory Pouchitis and U
Slide 14: Chronic Antibiotic-Refractory Pouchitis – Phase 2a Design & Expected Timeline
Lusvertikimab Chronic Antibiotic-Refractory Pouchitis – Phase 2a Design & Expected Timeline 12 Months 18 Months 30 Run-in Lusvertikimab IV post start post start Patients 4 weeks At week 0, 2, 6 and 10 Interim analysis on Primary efficacy endpoint: 50% of recruited patients reduction in stool frequen
Slide 15: CoTikiS – Lusvertikimab IV Phase 2 in Moderate-to-Severe UC
Lusvertikimab CoTikiS – POC in Chronic Inflammation Lusvertikimab IV Phase 2 in Moderate-to-Severe UC W0 W10 W38 Induction % of Completers Open Label % Completers Safety Screening IV infusions at Week 0, 2, 6 entering OLE Extension OLE OLE Follow-Up Lusvertikimab 50 98% 78% 150 patients 850mg pts •
Slide 16: Clinically and Statistically Meaningful Remission at Week 10 with Lusvertikimab
Lusvertikimab Clinically and Statistically Meaningful Remission at Week 10 with Lusvertikimab Primary Endpoint: Modified Mayo Score Clinical Remission at W10 Sustained benefit beyond W101 Improvement (MMS)*µ at W10 Δ 11.8%; p=0.066 100 Pooled 450/850 mg remission Placebo 450 850 450/850 30 remission
Slide 17: Induction Results at Week 10: Endoscopic Improvement and Remission
Lusvertikimab Induction Results at Week 10 Clinically meaningful and significant endoscopic improvement and remission Endoscopic Improvement** UC Endoscopic Index of Severity UCEIS*** Endoscopic Remission*at W10 at W10 change from baseline at W10 Δ 19.3%; p=0.027 Δ 11.7% Δ 31.9%; p=0.004 Δ 12.4% Pla
Slide 18: Induction Results at Week 10: Histologic Improvement
Lusvertikimab Induction Results at Week 10 Clinically meaningful and significant histologic and histo-endoscopic mucosal improvement Histological Improvement Histo-Endoscopic Mucosal Histological Geboes index at W10* Improvement (HEMI) at W10** change from baseline at W10 Δ 27.0%; p<0.01 Δ 21.0%; p=
Slide 19: CoTikiS – 850 mg Group More Severe Disease than 450 mg and/or Placebo Groups
Lusvertikimab CoTikiS – 850 mg Group More Severe Disease than 450 mg and/or Placebo Groups Placebo 450 mg (n=35) 850 mg (n=50) Total (n=134) (n=49) Age: mean (SD) 42.7 (15.9) 38.8 (10.5) 42.5 (15.1) 41.6 (14.4) Sex: male 28 (57.1%) 22 (62.9%) 27 (54.0%) 77 (57.5%) Weight (kg) mean (SD) 75.3 (15.2) 7
Slide 20: Lusvertikimab – Well Tolerated & Good Safety Profile
Lusvertikimab Lusvertikimab – Well Tolerated & Good Safety Profile Placebo 450 mg 850 mg Total (N=49) (N=36) (N=51) (N=136) N(%) [E] N(%) [E] N(%) [E] N(%) [E] At least one TEAE in induction phase 16 (32.7) [29] 17 (47.2) [33] 20 (39.2) [42] 53 (39.0) [104] At least one TEAE related to study treatme
Slide 21: Biomarker+ Could Boost Efficacy 4x in c.30-40% of UC Population Tested
Lusvertikimab Biomarker+ Could Boost Efficacy 4x in c.30-40% of UC Population Tested* Confirmatory ex-vivo data to be generated over next 2 years Clinical Remission (Placebo-adjusted) Clinical remission based on Lusvertikimab Biomarker Sensitivity Specificity 70 Δ 46.5% Lusv. 100% 85% % of Patients
Slide 22: TEDOPI®
TEDOPI® Most Advanced Therapeutic Cancer Immunotherapy Bringing new hope to patients in the fight against ICI resistant NSCLC
Slide 23: Tedopi®: An Immunotherapy Activating Specific T-Cells to Revive Anti-Tumor Response
Tedopi® An Immunotherapy Activating Specific T-Cells to Revive Anti-Tumor Response • Unique combination of neoepitopes: small peptides deriving from tumor specific antigens expressed in various cancers • Strong binding to HLA-A2 receptor (45% population) • Direct activation of tumor specific T-cells
Slide 24: ATALANTE: Survival Benefit with Tedopi® in Phase 3 in 3L HLA-A2+ NSCLC
Tedopi® ATALANTE: Survival Benefit with Tedopi® in Phase 3 in 3L HLA-A2+ NSCLC with Secondary Resistance to Immune Checkpoint Inhibitors OS rate at 12 months Significantly safer than SoC Overall Survival secondary resistance post anti-PD(L)1 44% in Tedopi® vs 27.5% in SoC 11% vs 35% grade 3-5 relate
Slide 25: ARTEMIA - Ongoing Tedopi® Phase 3 in HLA-A2+ NSCLC Patients Post ICI
Tedopi® ARTEMIA - Ongoing Tedopi® Phase 3 in HLA-A2+ NSCLC Patients Post Immune Checkpoint Inhibitors Tedopi® (n=242) KEY ELIGIBILITY CRITERIA Q3W for 6 SC cycles, Q3 2026 - HLA-A2+ - Metastatic squamous & non- then Q8W until end Year 1, then Q12W up to end Year 2 PRIMARY ENDPOINT: Overall Survival
Slide 26: Tedopi® Targets 100k Patients in 2nd Line NSCLC Post ICI
Tedopi® Tedopi® Targets 100k Patients in 2nd Line NSCLC Post ICI Tedopi® has the potential to become the new standard for recurrent patients in 2L NSCLC presenting HLA-A2 phenotype LUNG CANCER: Incidence of High prevalence, mortality and unmet need - worldwide advanced NSCLC in • 2nd most frequently
Slide 27: Additional Read-Out in 2026 in NSCLC, Ovarian and Pancreatic Cancer
Tedopi® Additional Read-Out in 2026 in NSCLC, Ovarian and Pancreatic Cancer Phase 2 ISS trials in combination with immunotherapy or chemotherapy treatments Maintenance setting post standard of care 2nd line post 1st line chemo IO TEDOVA - Ovarian Cancer TEDOPaM - Pancreatic Cancer CombiTED - NSCLC I
Slide 28: Financials
OS IMMUNO THERAPEUTICS Financials
Slide 29: Financials
Financials Company Overview Analyst Coverage Market Cap*: €75m Jamila El Bougrini (FR) Cash Position: €41.6m (June 30, 2025) (including €16.2m in short-term deposits) Arron Aatkar (UK) Cash Runway: Early Q4 2026 Jyoti Prakash (UK) Outstanding Shares: 22.5m Martial Descoutures (FR) Latest Equity Rais
Slide 30: Our 3-Year Development Plan Focused on Shareholder Value
Our 3-Year Development Plan Focused on Shareholder Value Strategy to maximize Return on Investment while managing risk: Large Partnered Indications vs • Large indication assets to be developed up to end of Phase 2 Smaller Go-Alone Indications • Smaller indication assets to be developed up to commerc
Slide 31: Immuno-Oncology & Immuno-Inflammation
Immuno-Oncology & Immuno-Inflammation Head Office Paris Office 22, boulevard Bénoni Goullin 10, Place de Catalogne 44200 Nantes, France 75014 Paris, France Company Information: http://ose-immuno.com/en/
OSE Immunotherapeutics — Investor Presentation (April 2026) on 6ix